The present study was designed to determine the effectiveness of an anti-VEGF monoclonal antibody, BD0801, combined with anti-PD-1/PD-L1 antibodies in preclinical tumor models to elucidate the mechanisms and support combination strategies in future clinical studies. The gene discussed is VEGFA; the disease is neoplasm.